We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.00 | 1.95 | 2.05 | 2.00 | 2.00 | 2.00 | 294 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.38 | 15.51M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/5/2020 06:50 | one smudge in of advice when reading research notes from brokers look at the accounts to see how much they are getting paid by the repressive Company it may have a bearing on what is been wrote | best1467 | |
01/5/2020 06:47 | Of course iv requires a visit to a hospital for a vulnerable person. So assuming this crisis lasts for a quite a while, the advantage of an oral therapy is clear! | nobbygnome | |
01/5/2020 06:40 | In these times a pretty good update Money to Norgine is fair enough..lets see what comes from the review. As it states still positives that are not in question in the review that can be used moving forward. Positive re US deals..... "significant interest from a range of companies" and "talks have advanced in recent weeks". So hopefully not far away now. Norgine sales have seen growth Supplies ok and thus "will be able to supply US promptly"......very promising line China still moving forward during this period of lockdown...massive market Paediatric study slight delay..fair enough.Great potential there. Plenty of cash in hand into 2021 Great line in CEO statement "confident of the pressing need for our product as an IV alternative" IV alternative for the worlds biggest deficiency, and a pressing need. US market is massive and they have the supplies to move straight into the US. Looking forward to that update. | peachie 74 | |
01/5/2020 06:29 | The reality is all that matters from a share price point of view ultimately is the US deal. Because of the precipitate decline there is plenty of upside if they get a half decent deal. It's an open goal really, although not sure what will happen today. If there is a sell off because of the repayment of the milestone, then it will be a good buying opportunity. | nobbygnome | |
01/5/2020 06:23 | yesterday’s rise probably due to this... “we have been able to advance discussions with interested parties in recent weeks“ | ny boy | |
01/5/2020 06:18 | Trading seems good, no disruption to supply. Money back to Norgine that was expected. | montyhedge | |
01/5/2020 06:15 | Yes good and bad in the update. Ultimately they still have cash into the first quarter of next year so under no real time pressure for the US negotiations. It sounds like progress has been made with those negotiations and I think the current lockdown helps. Other companies I am involved in have said that it is easier to speak to the required people at present which facilitates deal making. | nobbygnome | |
01/5/2020 06:06 | Trading update released. They agreed to repay Norgine the money for the H2H milestone. Not much else. | crankyman | |
01/5/2020 00:35 | Bought into this yesterday ( not on a large scale) but intrigued by the product. Happy as anything to see a 21% rise in one day. Nice to see anything going green at the moment! | decolady1 | |
30/4/2020 19:54 | But it has been his thing for a long time. I think he would be against a takeover at this stage. Who knows !? | peachie 74 | |
30/4/2020 19:06 | I'm sure he would not be against a takeover if he holds 10% even at today's price. In presentations he always said that his aim was to make sure the small investors were looked after/did well as they normally get screwed over. Perhaps the big shareholders didn't like that mentality... | ekcs | |
30/4/2020 15:13 | Let’s see after the bell, if there is any broker news or press, could be investorS just switched into this for safety and the sp, had simply got too cheap and was not valuing anything for FDA broad label approval, last summer? | ny boy | |
30/4/2020 14:48 | Not convinced he was/is against a take over. Everyone has a price. I’m sure he would not mind pocketing 30-50 million quid. | crankyman | |
30/4/2020 14:33 | Nobby I did mention that a takeover could possibly be the only positive from the recent departure of CS aS founder of the company He may have been totally against it .That could be behind the recent rise who knows but while depending on price I would imagine we would not get the long term true value if a takeover is about to happen My guess would be around the £2.00/£2.50 level where as with the right USA partner deal and everything going to plan in China in 2/3 years we could be closer to the £4/5 level even higher if the trial with P20 I think it is goes well | best1467 | |
30/4/2020 14:05 | It's a risk off day, so this is a good performance. If it was a risk on day, perhaps this would have been back to 150p. | montyhedge | |
30/4/2020 13:36 | It’s possible some people who used to hold have decided to return | crankyman | |
30/4/2020 12:14 | Of course taking a breather but this is a strong move on a down day for the market. Must be something going on, no rns yet. | montyhedge | |
30/4/2020 11:47 | Above for anyone thinking of investing. Great read And another below | peachie 74 | |
30/4/2020 11:24 | Good progress, await with great interest news of a US commercialisation deal or takeover Happy to hold GLA | ny boy | |
30/4/2020 11:19 | 157 million MK is peanuts for a company with a product to revolutionise a multi billion dollar industry worldwide. Something has got to be around the corner | peachie 74 | |
30/4/2020 11:16 | He does retain his holding. 9% if I remember About 50% of these are in “safe hands” I think | peachie 74 | |
30/4/2020 11:04 | Latest resistance Levels Resistance1: 159.00p Resistance2: 185.71p | ny boy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions